Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Operating Leases (2024 - 2025)

Xilio Therapeutics' Operating Leases history spans 2 years, with the latest figure at $6.0 million for Q3 2025.

  • For Q3 2025, Operating Leases fell 17.94% year-over-year to $6.0 million; the TTM value through Sep 2025 reached $6.0 million, down 17.94%, while the annual FY2024 figure was $7.0 million, N/A changed from the prior year.
  • Operating Leases for Q3 2025 was $6.0 million at Xilio Therapeutics, down from $6.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $7.9 million in Q1 2024 and bottomed at $6.0 million in Q3 2025.